



CHANDAN HEALTHCARE LIMITED

Reg. Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: L85110UP2003PLC193493

TELNO.: -8069366666 Email: secretarial@chandan.co.in

www.chandandiagnostic.com

Date: May 29, 2026

To,
The Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra- Kurla Complex, Bandra (East),
Mumbai - 400 051

Symbol: CHANDAN
ISIN: INE0B2N01016

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sub: Outcome of Board meeting held on Friday, May 29, 2026, at 5:00 P.M. (IST)

Dear Sir/Madam,

Pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of Chandan Healthcare Limited ("the Company") at their meeting held today on Friday, May 29, 2026, has inter-alia, considered and approved:

- 1. Audited Financial Results (Standalone & Consolidated)** of the Company for the Half Year and Financial Year ended March 31, 2026, along with the Audit Report of the Auditors thereon pursuant to Regulation 33 of SEBI (Listing Obligations & Disclosures Requirements) Regulations, 2015;

Accordingly, pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we are enclosing the following:

- i. Statements showing the Audited Standalone Financial Results** for the half year and Financial Year ended March 31, 2026; ('Annexure – A1').
- ii. Statements showing the Audited Consolidated Financial Results** for the half year and Financial Year ended March 31, 2026; ('Annexure – A2').
- iii. Audit Report on the Standalone Financial Results** for the half year and Financial Year ended March 31, 2026; ('Annexure – A3').
- iv. Audit Report on the Consolidated Financial Results** for the half year and Financial Year ended March 31, 2026; ('Annexure – A4').

In Compliance with Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended by the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016, vide notification no. SEBI/LAD-NRO/GN/2016-17/001 dated 25th May, 2016 and Circular no. CIR/CFD/CMD/56/2016 dated 27th May, 2016, we hereby declare that the Statutory Auditors of the Company, M/s MSNT & ASSOCIATES LLP, Chartered Accountants (FRN: 018542C), have issued an Audit Report with unmodified opinion on the Audited Financial Results of the Company for the half year and year ended March 31, 2026. A



CHANDAN HEALTHCARE LIMITED

Reg. Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: L85110UP2003PLC193493

TELNO.: -8069366666 Email: secretarial@chandan.co.in

www.chandandiagnostic.com

Declaration pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with respect to Audit Report with unmodified opinion is enclosed herewith as '**Annexure B**'.

- 2. Re-appointment of Internal Auditor:** Re-appointment of M/s. Renu Agrawal & Co., Chartered Accountants, as an Internal Auditor of the Company, as per the recommendation of the Audit Committee, to conduct the Internal Audit for the Financial Year 2026-27.
- 3. Re-appointment of Cost Auditor:** Re-appointment of M/s. Rahul Jain & Associates, Cost Accountants, as the Cost Auditors of the Company, as per the recommendation of the Audit Committee, to conduct the Cost Audit for the Financial Year 2026-27.

The disclosures required pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, regarding the aforesaid reappointments of Internal Auditor and Cost Auditor are enclosed as **Annexure I & II** respectively.

- 4. Statement of Deviation or Variation in Utilisation of Funds** Raised through Initial Public Offer and Preferential Issue of Warrants under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended March 31, 2026.

The Board meeting commenced at 05:00 P.M. and concluded at 08:30 P.M.

Kindly take the above information on record. The above information is also available on the Company's website at www.chandandiagnostic.com.

Thanking you,

Yours sincerely,

For Chandan Healthcare Limited

Rajeev Nain
Company Secretary & Compliance Officer

Encl.: as above



MSNT & ASSOCIATES LLP

CHARTERED ACCOUNTANTS

Independent Auditor's Report on quarterly and year to Date Audited Standalone financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,
The Board of Directors,
Chandan Healthcare Limited,
Lucknow

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying statement of quarterly and year to date standalone financial results of M/s. *Chandan Healthcare Limited* (the "Company") for the quarter ended March 31, 2026, and for the year ended March 31, 2026 (the "Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement.

- I. Is presented in accordance with the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- II. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and other comprehensive profit and other financial information for the quarter ended March 31, 2026, as well as year to date results for the period from April 1 2025 to 31 March 2026.

Basis for Opinion

We conducted our audit in accordance with the Standard on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibility under those Standards is further described in the Auditor's Responsibility for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statement under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis of our opinion.

📍 : **Head Office:** - A-40, I-Thum, Tower-B, 10th Floor, Unit No. 1033, Sector 62, Noida-201005.
Branch Office: - 239, Satra Plaza, Sector-19 D, Palm Beach Road, Vashi, Navi Mumbai-400703.
☎ : CA Saurabh Tyagi: 7718802884, CA Navodit Tyagi: 9167436404, CA Manoj Modi: 9022059201.
✉ : saurabh@msnt.in navodit@msnt.in manoj@msnt.in



Management's Responsibilities for the Standalone Financial Results

The Statement have been prepared on the basis of the standalone financial statements. The Company's Board of Directors are responsible for the preparation of the Statement that give a true and fair view of the net profit and other comprehensive profit and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial control with reference to financial statements in place and operating effectiveness of such control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to



continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the statement, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Statement includes the results for the quarter ended March 31, 2026, being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2026, and the unaudited year – to date figures up to the First nine months of the current financial year as per books of accounts.

As Per MCA Notification dated 16th February 2015, companies whose shares are listed on SME exchange as referred to in chapter XB of the SEBI (Issue of capital & disclosures requirement) regulation 2009 are exempted from the compulsory requirement of adoption of IND AS. As the company is covered under the exempted category, it has not adopted IND AS for the preparation of financial statement.

Figures for the previous periods/year have been regrouped, restated and/or reclassified whenever considered necessary to make them comparable to the current periods.

Our opinion on the statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the financial information certified by the Board of Directors.

For MSNT & ASSOCIATES LLP
Chartered Accountants
Firm Registration No.018542C/C400322



Navodit Tyagi
Partner
Membership No.-533375
UDIN No: 26533375VKAQQE6163
Place: Noida
Date: 29/05/2026

Audited Standalone Statement Of Financial Results For The Quarter Ended 31st March, 2026

Particulars	31st March, 2026		31st March, 2025		31st March, 2026		31st March, 2025	
	Audited		Unaudited		Audited		Audited	
	31st March, 2026	31st December, 2025	31st March, 2025	31st March, 2026	31st March, 2026	31st March, 2025	31st March, 2026	31st March, 2025
I. Revenue from operations	4,477.09	3,569.71	3,705.25	15,664.73	12,916.42			
II. Other income	199.79	67.61	190.28	412.50	204.89			
III. Total revenue(II+I)	4,676.88	3,637.32	3,895.53	16,077.23	13,121.31			
IV. Expenses:								
Cost of material consumed	604.09	322.93	573.55	2,281.00	1,542.19			
Purchase of stock-in-trade	136.17	167.10	139.71	568.45	446.61			
Change in inventories of finished goods, work-in-progress and stock-in-trade.	18.05	(7.65)	(8.65)	48.65	(19.18)			
Employee benefits expense.	1,135.38	1,034.94	838.27	3,865.05	3,338.56			
Finance Costs	137.34	93.75	98.02	442.89	356.90			
Depreciation and amortisation expense	233.68	236.99	241.56	951.43	642.24			
Other expenses	1,453.00	1,051.20	1,124.17	4,258.46	3,997.44			
Total expenses (IV)	3,717.71	2,899.26	3,006.63	12,415.93	10,304.76			
V. Profit/(loss) before exceptional & extraordinary items and tax (III-IV)	959.17	738.06	888.90	3,661.30	2,816.55			
VI. Exceptional items*	64.51	206.46	-	270.97	-			
VII. Profit/(loss) before extraordinary items and tax (V-VI)	894.66	531.60	888.90	3,390.33	2,816.55			
VIII. Extraordinary items	-	-	-	-	-			
IX. Profit/(loss) before tax (VII- VIII)	894.66	531.60	888.90	3,390.33	2,816.55			
X. Tax expense of continuing operation:-								
Current tax	203.64	170.39	273.95	810.99	700.14			
Deferred tax	9.28	(35.02)	(27.09)	45.21	38.61			
Tax expense(X)	212.92	135.37	246.86	856.20	738.75			
XI. Profit/(loss) for the period from continuing operations(after tax) (IX-X)	681.74	396.23	642.04	2,534.13	2,077.80			
XII. Profit/(loss) from discontinuing operations	-	-	-	-	-			
XIII. Tax expense of discontinuing operations	-	-	-	-	-			
XIV. Profit/(loss) from discontinuing operations (after tax) (XII-XIII)	-	-	-	-	-			
XV. Share of (profit)/ loss transferred to minority interest	-	-	-	-	-			
XVI. Profit/ (Loss) after tax attributable to owners of the company (XI+XIV+XV)	681.74	396.23	642.04	2,534.13	2,077.80			
XVII. Earnings per equity share:								
(1) Basic	2.79	1.62	2.92	10.36	10.10			
(2) Diluted	2.51	1.62	2.92	10.08	10.10			

*During the period, pursuant to the implementation of the New Labour Codes and the resultant change in the definition of wages, the Company recognised additional defined benefit obligations based on actuarial valuation in accordance with Accounting Standard (AS) 15 – Employee Benefits. The impact relating to employee service in prior periods has been recognised as past service cost and disclosed as an Exceptional Item.

As per our report of even date attached

For M/s Misnt & Associates LLP

Chartered accountants

Firm registration no. :- 018542C/400322

Navodit tyagi

Partner

Membership no. :- 533375

UDIN no. :- 2653375VKAAQQE6163

Place :- Noida

Date :- 29th May 2026

For & on behalf of the board of directors

CHANDAN HEALTHCARE LIMITED



Amar Singh

Managing director

Din. :- 01096328

Place :- Lucknow

Date :- 29th May 2026

Asmita Singh

Managing director

Din. :- 01098055

Place :- Lucknow

Date :- 29th May 2026

Rajeev Nain

CFO & Company secretary

Place :- Lucknow

Date :- 29th May 2026

COMPANY NAME :- CHANDAN HEALTHCARE LIMITED

CIN :- L85110UP2003PLC193493

REGISTERED ADDRESS :- Biotech Park, Sector G, Jankipuram, Kursi Road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Audited Standalone Statement Of Assets & Liabilities As At 31st March, 2026

Particulars	Note No.	Figures As At 31st March, 2026	Figures As At 31st March, 2025
I. EQUITY AND LIABILITIES			
(1) Shareholder's funds			
(a) Share capital	3	2,445.21	2,445.21
(b) Reserves and surplus	4	14,182.75	9,626.41
(c) Money received against share warrants	5	111.25	-
(2) Share application money pending allotment			
(3) Minority interest			
(4) Non-current liabilities			
(a) Long-term borrowings	6	2,897.34	2,214.46
(b) Deferred tax liabilities(net)	7	235.54	190.33
(c) Other long-term liabilities	8	2.20	2.45
(d) Long term provisions	9	413.86	313.01
(5) Current liabilities			
(a) Short-term borrowings	10	1,004.89	1,105.92
(b) Trade payables	11	-	-
(i) Total outstanding dues of micro & small enterprises.		397.32	257.82
(ii) Total outstanding dues of creditors other than micro & small enterprises.		609.33	776.16
(c) Other current liabilities	12	834.99	693.47
(d) Short term provisions	13	96.22	65.11
TOTAL		23,230.90	17,690.35
II. ASSETS			
(1) Non-current assets			
(a) Property, plant & equipments & intangible assets	14	-	-
(i) Property, plant & equipments		9,574.33	7,148.48
(ii) Intangible assets		-	-
(iii) Capital work in progress		1,189.89	410.12
(iv) Intangible assets under development		-	-
(b) Non-current investments	15	1,779.26	2,598.61
(c) Deferred tax assets(net)	-	-	-
(d) Long-term loans and advances	16	100.00	-
(e) Other non-current assets	17	202.05	222.47
(2) Current assets			
(a) Current investments	18	639.30	1,059.00
(b) Inventories	19	1,623.18	1,711.99
(c) Trade receivables	20	4,421.50	3,131.03
(d) Cash and bank balances	21	313.56	603.10
(e) Short-term loans and advances	22	2,649.37	295.93
(f) Other current assets	23	738.46	509.62
TOTAL		23,230.90	17,690.35

As per our report of even date attached

For M/s Msnt & Associates LLP

Chartered accountants

Firm registration no. :- 018542C/C400322

Navodit tyagi

Partner

Membership no. :- 533375

UDIN no. :- 26533375VKAQQE6165

Place :- Noida

Date :- 29th May 2026



For & on behalf of the board of directors
CHANDAN HEALTHCARE LIMITED

Amar singh
Managing director

Din. :- 01096328

Place :- Lucknow

Date :- 29th May 2026

Asmita singh

Managing director

Din. :- 01098055

Place :- Lucknow

Date :- 29th May 2026



Rajeev Nain

CFO & Company secretary

Place :- Lucknow

Date :- Lucknow

COMPANY NAME :- CHANDAN HEALTHCARE LIMITED

CIN :- L85110UP2003PLC193493

REGISTERED ADDRESS :- Biotech Park, Sector G, Jankipuram, Kursi Road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Audited Standalone Standalone Statement Of Cash Flow For The Year Ended 31st March, 2026

Particulars	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
A. Cash flow arising from operating activities		
Profit / (Loss) before tax	3,390.33	2,816.55
Adjustments related to non-cash & non operating transactions:		
Non cash transactions		
Depreciation & amortisation of fixed assets	951.43	642.24
Bad Debts & Balances written off/written back	26.47	(82.47)
Preliminary expenses written off	-	-
Re-measurement (gains) / loss on defined benefit plans	136.47	71.77
Provision for doubtful debts	(18.71)	15.28
Provision for obsolete inventories	(0.33)	10.10
Loss(gain) on account of foreign exchange fluctuations	-	-
Other non-cash transactions(specify nature)	-	-
Non operating transactions		
Interest on borrowing	436.70	341.17
Loss/(profit) on the sale of property, plant & equipments & intangible assets	-	-
Loss/(profit) on the sale of investments	-	-
Interest income	(386.87)	(45.32)
Dividend income	-	-
Other non-operating transactions(specify nature)	-	-
Operating profit/(loss) before working capital changes	4,535.48	3,769.32
Adjustment for change in working capital:		
(Increase) / Decrease in inventories	89.14	(1,076.28)
(Increase) / Decrease in trade receivables	(1,298.23)	(658.77)
(Increase) / Decrease in other current assets	(208.42)	(327.37)
(Decrease) / Increase in trade payables	(27.33)	426.26
(Decrease) / Increase in other current liabilities	181.97	(756.47)
Net cash (used in) / generated from operating activities	3,272.61	1,376.69
Income taxes refund / (paid), net	(856.20)	(738.75)
Net cash flow from operating activities(A)	2,416.42	637.94
B. Cash flow arising from investing activities		
Sale/(Purchase) of tangible and intangible assets	(4,157.05)	(3,848.04)
Sale/(Purchase) of non current & current investments	(1,214.39)	(2,283.76)
Interest income	386.87	45.32
Dividend income	-	-
Net cash flow from investing activities(B)	(4,984.57)	(6,086.48)
C. Cash Flow Arising From Financing Activities		
Proceeds from issuance of share capital(Including share Warrants)	2,133.46	6,227.13
Proceeds from/(Payment of) long term & short term borrowings	581.85	412.54
Finance cost paid (including processing fees)	(436.70)	(341.17)
Dividend paid	-	(300.00)
Net cash flow from financing activities(C)	2,278.61	5,998.50
Net increase/decrease in cash or cash equivalents(A+B+C)	(289.54)	549.96
Cash and cash equivalents at the beginning of the period	603.10	53.14
Cash and cash equivalents at the end of the period	313.56	603.10

As per our report of even date attached
For M/s Msnt & Associates LLP
Chartered accountants


Navodit tyagi
Partner

Membership no. :- 533375

UDIN no. :- 26533375VKAQQE6163

Place :- Noida

Date :- 29th May 2026




For & on behalf of the board of directors
CHANDAN HEALTHCARE LIMITED

Amar singh
Managing director
Din. :- 01096328
Place :- Lucknow
Date :- 29th May 2026

Asmita singh
Managing director
Din. :- 01098055
Place :- Lucknow
Date :- 29th May 2026

Rajeev Nain
CFO & Company secretary
Place :- 29th May 2026
Date :- Lucknow



Chandan Healthcare Limited
L85110UP2003PLC193493
Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.
(All amounts are in ₹ lakhs, unless otherwise stated)

Notes to financial statements for the Year ended 31st March, 2026

Note No. :- 32 : Disclosure regarding Transactions with Related Parties in terms of Accounting Standard - 18

Name of the related party	Nature of the relationship 31st March	Nature of the relationship 31st
	2026	March 2025
A. Enterprises that directly or indirectly control/controlled by/under common control with, the reporting enterprise		
Chandan Diagnostic Limited- PAN: AABCC9315J	Holding 67.99% of share capital	Holding 67.99% of share capital
Chandan Hospital Limited - PAN: AABCC9314K	Common director	Common director
Indira Diagnostic Centre & Blood Bank Limited - PAN: AABCI0214L	Holding 100% of share capital	Holding 100% of share capital
Chandan Pharmacy Limited - PAN: AAHCC1459M	Holding 53.56% of share capital	Holding 53.56% of share capital
Cendana Pharmaceuticlas Private Limited - PAN: AAKCC1991P	Common director	Common director
Amaranita Holdings (I) Private Limited - PAN: AAHCA1540R	Common director	Common director
Chandan Singh Foundation - PAN: AAATC2479F	Common director and trustee	Common director and trustee
Healthrely Private Limited- PAN:AAGCH9438N	Common director	Common director
Chandan Cancer Institute Limited-PAN:AALCC9159N	Common director	Common director
Chandan Super Speciality Hospital Limited- PAN: AALCC1234A	Common director	Common director
AMARANITA HOSPITALITY PRIVATE LIMITED: ABFCA4827Q	Common director	-
CHANDAN HEALTHCARE PROJECTS PRIVATE LIMITED: AANCC6242L	Common director	-
CHANDAN CRADLE LIMITED: AANCC3763A	Common director	-
B. Individuals owning, directly or indirectly, an interest in the voting power of the reporting enterprise that gives them control or significant influence over the enterprise, and relatives of any such individual		
Dr Amar Singh - PAN: AGQPS5396H - DIN: 01096328	Managing director of company (MD)	Managing director of company (MD)
Asmita Singh - PAN: AWSPS3853M - DIN: 01098055	Managing director of company (MD)	Managing director of company (MD)
Virendra Singh - PAN: AFSPS0571B - DIN: 01099343	Director of company*	Director of company*
Vinay Lamba - PAN: AAXPL5673R - DIN: 01220153	Director of company	Director of company
Vijay Singh - PAN: AILPS1503P - DIN: 02778087*	Director of company*	Director of company
Aasti Singh - PAN: FRPPS0695A - DIN: 06973933*	Relative of director	Director of company
Anant Singh - PAN: AWSPS3852L - DIN: 00969364*	Relative of director	Director of company
Rajeev Nain - PAN: AIVPN6380K	Key managerial personnel (CFO & Company secretary)	Key managerial personnel (CFO & Company secretary)
Mohammad Mohsin Rizvi - PAN: AQXPR3626G	Relative of director	Relative of director
Anita Singh - PAN: ARVPS1208G	Relative of director	Relative of director
Vishal Lamba - PAN: ABUPL4208N	Relative of director	Relative of director
Ajai Singh - PAN: AHNPS7885B	Relative of director	Relative of director
Nisha Lamba - PAN: AATPL6545J	Relative of director	Relative of director
Pragya Singh - PAN: DJVPS5075J	Relative of KMP	Relative of KMP
Vikash Lamba - PAN: ACLPL2389Q	Relative of director	Relative of director
Deepa Lamba - PAN: AAYPL1519B	Relative of director	Relative of director
Shailendra Singh- PAN CBEPS0038M	Relative of director	-
Anshu Lamba - PAN: ABQPL8606C	Relative of director	Relative of director

During the financial year, the company divested its investments in certain subsidiaries and associates. As a result of these transactions, these entities are no longer classified as subsidiaries or associates in the company's financial statements.

* During the financial year, the individual ceased to serve as a director

a. Details of transactions with related parties and amounts (receivable)/payable as at the beginning and end of the year:

Name of related party	Nature of Transaction	Standalone figures for the year ended 31st March, 2026	Standalone figures for the half year ended 31st March, 2026
Dr Amar Singh	Opening Balance Payable(Receivable)	3.32	24.56
	Receipt	63.75	53.75
	Salary	46.71	8.71
	Payment	(223.64)	(184.98)
	Reimbursement	128.59	116.69
	Closing Balance Payable(Receivable)	18.72	18.72
	Asmita Singh	Opening Balance Payable(Receivable)	4.82
Reimbursement		0.04	0.25
Receipt		22.56	22.56
Salary		84.89	37.29
Payment		(115.05)	(67.82)
Closing Balance Payable(Receivable)		(2.75)	(2.75)
Vijay Singh		Opening Balance Payable(Receivable)	1.00
	Reimbursement	0.44	0.44

	Payment	(36.27)	(11.50)
	Salary	36.19	9.59
	Closing Balance Payable(Receivable)	1.36	1.36
Rajeev Nain	Opening Balance Payable(Receivable)	2.91	4.59
	Reimbursement	0.92	0.96
	Payment	(49.33)	(11.29)
	Salary	47.99	8.22
	Closing Balance Payable(Receivable)	2.49	2.49
Vikas Lamba	Opening Balance Payable(Receivable)	-	(2.10)
	Payment	(18.04)	(16.24)
	Salary	8.04	8.04
	Reimbursement	8.66	8.96
	Closing Balance Payable(Receivable)	(1.34)	(1.34)
Vishal Lamba	Opening Balance Payable(Receivable)	-	(0.03)
	Payment	(1.62)	(1.60)
	Reimbursement	1.62	1.62
Deepa Lamba	Opening Balance Payable(Receivable)	-	1.00
	Salary	8.00	7.00
	Payment	(6.53)	(6.53)
	Closing Balance Payable(Receivable)	1.47	1.47
Shailendra Singh	Opening Balance Payable(Receivable)	0.63	0.63
	Reimbursement	1.37	1.37
	Payment	(1.37)	(1.37)
	Closing Balance Payable(Receivable)	0.63	0.63
Chandan Hospital Limited	Opening Balance Payable(Receivable)	(160.64)	(1,312.09)
	Receipt	4,286.73	2,416.53
	Loan Interest income	(133.41)	(78.22)
	Loan Payment	(1,300.00)	(1,355.19)
	Sales	(579.54)	39.18
	Payment	(2,900.36)	(497.43)
	Closing Balance Loan Payable(Receivable)	(1,433.41)	(1,433.41)
	Closing Balance Payable(Receivable)	646.19	646.19
Chandan Pharmacy Limited	Opening Balance Payable(Receivable)	(3.78)	10.47
	Opening Balance Investment in equity	(474.00)	474.00
	Sales	(28.17)	(6.99)
	Purchase	21.74	14.24
	Receipt	10.96	(38.04)
	Loan Interest income	(24.58)	(24.58)
	Loan receipt	742.03	742.03
	Loan Payment	(1,603.70)	(1,603.70)
	Payment	(1.45)	19.61
	Closing Balance Investment in equity	(474.00)	474.00
	Closing Balance Loan Payable(Receivable)	(886.25)	(886.25)
	Closing Balance Payable(Receivable)	(0.71)	(0.71)
	Opening Balance Loan Payable(Receivable)	(295.93)	(295.93)
	Loan Interest income	(33.78)	(33.78)
	CSR	55.86	55.86
	Payment	(71.19)	(71.19)
	Closing Balance Loan Payable(Receivable)	(329.71)	(329.71)
	Closing Balance Payable(Receivable)	(15.33)	(15.33)
Chandan Diagnostic Limited	Opening Balance Payable(Receivable)	-	(1.00)
	Opening Balance Investment in equity	(65.85)	(65.85)
	Closing Balance Investment in equity	(65.85)	(65.85)
	Closing Balance Payable(Receivable)	(1.01)	(1.00)
Indra Diagnostic Centre & Blood Bank Limited	Opening Balance Payable(Receivable)	344.30	657.79
	Opening Balance Investment in equity	(491.69)	(491.68)
	Receipt	15.65	(328.89)
	Payment	(344.84)	(329.19)
	Closing Balance Investment in equity	(491.68)	(491.68)
	Closing Balance Payable(Receivable)	(0.30)	(0.30)
Cendana Pharmaceuticals	Opening Balance Payable(Receivable)	(199.65)	(38.32)
	Receipt	170.26229	0.26
	Payment	(35.97)	(0.86)
	Purchase	35.19	0.57
	Sales	(9.03)	(0.84)
	Closing Balance Payable(Receivable)	(39.19)	(39.19)
Chandan Super Speciality Hospital Limited	Opening Balance Payable(Receivable)	(7.91)	(99.08)
	Receipt	185.08	178.23
	Payment	-	0.02
	Sales	(184.15)	(86.15)
	Closing Balance Payable(Receivable)	(6.98)	(6.98)
CHANDAN HEALTHCARE PROJECTS PRIVATE LIMITED	Share Purchase	(1.00)	(1.00)
	Closing Balance Investment in equity	(1.00)	(1.00)



MSNT & ASSOCIATES LLP

CHARTERED ACCOUNTANTS

Independent Auditor's Report on Quarterly and Year to Date Audited Consolidated financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,
The Board of Directors,
Chandan Healthcare Limited,
Lucknow

Report on the audit of the Consolidated Financial Results

Opinion

We have audited the accompanying Statement of quarterly and year to date Consolidated Financial Results of *M/s. Chandan Healthcare Limited* (hereinafter referred to as the "Holding company") and its subsidiaries (holding company and its subsidiaries together referred to as "the Group"), ("the Statement"), being submitted by the holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements/ financial information of subsidiaries, the Statement:

- a) includes the results of the following entities:
 - I. Chandan Pharmacy Limited.
 - II. Chandan Diagnostic Limited.
 - III. Indira Diagnostic Centre & Blood Bank Limited.
 - IV. Chandan Healthcare Projects Private Limited.
- b) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations, as amended; and
- c) gives a true and fair view, in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of consolidated net profit after tax and other comprehensive profit and other financial information of the Group for the quarterly ended March 31, 2025, and for the period from April 01, 2025 to March 31, 2026.



📍 : **Head Office:** - A-40, I-Thum, Tower-B, 10th Floor, Unit No. 1033, Sector 62, Noida-201005.
Branch Office: - 239, Satra Plaza, Sector-19 D, Palm Beach Road, Vashi, Navi Mumbai-400703.
☎ : CA Saurabh Tyagi: 7718802884, CA Navodit Tyagi: 9167436404, CA Manoj Modi: 9022059201.
✉ : saurabh@msnt.in navodit@msnt.in manoj@msnt.in

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Results* section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Consolidated Financial Results

The Statement, which is the responsibility of the Holding Company's management and has been approved by the Holding Company's Board of Directors, has been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of Statement that give a true and fair view of the net profit and other comprehensive profit and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standard prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

The respective Board of Directors of the companies included in the Group, are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies included in the Group entities are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.



As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the statement, including the disclosures, and whether the statement represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.



Other Matters

The consolidated annual financial results include the audited financial results of four subsidiaries. The financial statements of these subsidiaries reflect the Group's share of total assets of Rs. 7,229.44 lakhs (before consolidation adjustments) as at 31st March, 2026, the Group's share of total revenue from operations of Rs. 12,064.73 lakhs (before consolidation adjustments), the Group's share of total income of Rs. 351.05 lakhs (before consolidation adjustments), and the Group's share of net cash Inflows of Rs. 27.03 lakhs (before consolidation adjustments) for the year ended on that date. Out of these four subsidiaries, the financial statements of **Chandan Pharmacy Limited** have been audited by us, while the financial statements of the other three subsidiaries have been audited by their respective independent auditors. The independent auditors' reports on the financial statements of these three entities have been furnished to us by the management, and our opinion on the consolidated annual financial results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the reports of such auditors and the procedures performed by us as stated in the paragraph above.

The Statement includes the results for the Quarter ended March 31, 2026, being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2026, and the unaudited year – to date figures up to the first 9 months of the current financial year as per books of accounts.

As Per MCA Notification dated 16th February 2015, companies whose shares are listed on SME exchange as referred to in chapter XB of the SEBI (Issue of capital & disclosures requirement) regulation 2009 are exempted from the compulsory requirement of adoption of IND AS. As the company is covered under the exempted category, it has not adopted IND AS for the preparation of financial statement.

Figures for the previous periods/year have been regrouped, restated and/or reclassified whenever considered necessary to make them comparable to the current periods.

Our opinion on the statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the financial information certified by the Board of Directors.

For MSNT & ASSOCIATES LLP

Chartered Accountants

Firm Registration No.018542C/C400322



Navodit Tyagi

Partner

Membership No.-533375

UDIN No: 26533375SHEYQZ6542

Place: Noida

Date: 29th May 2026

COMPANY NAME :- CHANDAN HEALTHCARE LIMITED

CIN :- L85110UP2003PLC193493

REGISTERED ADDRESS :- Biotech Park, Sector G, Jankipuram, Kursi Road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Audited Consolidated Statement Of Financial Results For The Quarter Ended 31st March, 2026

Particulars	Quarter Ended			Year Ended	
	31st March, 2026	31st December, 2025	31st March, 2025	31st March, 2026	31st March, 2025
	Audited	Unaudited	Unaudited	Audited	Audited
I. Revenue from operations	7,558.36	6,500.74	6,284.61	27,639.44	23,012.08
II. Other income	182.36	76.55	242.16	427.85	293.51
III. Total revenue(I+II)	7,740.72	6,577.29	6,506.77	28,067.29	23,305.59
IV. Expenses:					
Cost of material consumed	605.12	317.68	565.00	2,286.65	1,545.88
Purchase of stock-in-trade	2,815.48	2,936.62	2,384.05	11,359.87	9,498.14
Change in inventories of finished goods, work-in-progress and stock-in-trade.	54.17	(249.48)	92.41	(278.05)	(282.32)
Employee benefits expense.	1,289.61	1,167.56	971.90	4,419.65	3,886.11
Finance Costs	180.22	128.02	129.61	588.19	457.60
Depreciation and amortisation expense	244.68	240.40	289.56	977.98	674.48
Other expenses	1,551.10	1,144.17	1,228.18	4,594.80	4,319.15
Total expenses (IV)	6,740.38	5,684.97	5,640.71	23,949.09	20,099.04
V. Profit/(loss) before exceptional & extraordinary items and tax (III-IV)	1,000.34	892.32	866.06	4,118.20	3,206.55
VI. Exceptional items*	68.67	222.87	-	291.54	-
VII. Profit/(loss) before extraordinary items and tax (V-VI)	931.67	669.45	866.06	3,826.66	3,206.55
VIII. Extraordinary items	-	-	-	-	-
IX. Profit/(loss) before tax (VII- VIII)	931.67	669.45	866.06	3,826.66	3,206.55
X. Tax expense of continuing operation:-					
Current tax	227.31	208.50	290.98	934.31	830.58
Deferred tax	2.98	(42.28)	(34.56)	36.99	24.34
Tax expense(X)	230.29	166.22	256.42	971.30	854.92
XI. Profit/(loss) for the period from continuing operations(after tax) (IX-X)	701.38	503.23	609.64	2,855.36	2,351.63
XII. Profit/(loss) from discontinuing operations	-	-	-	-	-
XIII. Tax expense of discontinuing operations	-	-	-	-	-
XIV. Profit/(loss) from discontinuing operations (after tax) (XII-XIII)	-	-	-	-	-
XV. Share of (profit)/ loss transferred to minority interest	(9.59)	(49.42)	(7.48)	(149.52)	(134.55)
XVI. Profit/ (Loss) after tax attributable to owners of the company (XI+XIV+XV)	691.79	453.81	602.16	2,705.74	2,217.08
XVII. Earnings per equity share:					
(1) Basic	2.83	1.86	2.64	11.07	10.78
(2) Diluted	2.53	1.86	2.64	10.76	10.78

*During the period, pursuant to the implementation of the New Labour Codes and the resultant change in the definition of wages, the Company recognised additional defined benefit obligations based on actuarial valuation in accordance with Accounting Standard (AS) 15 – Employee Benefits. The impact relating to employee service in prior periods has been recognised as past service cost and disclosed as an Exceptional Item.

As per our report of even date attached

For M/s Msnt & Associates LLP

Chartered accountants

Firm registration no. :- 018542C/C400322

Navodit Tyagi

Partner

Membership no. :- 533375

UDIN no. :- 26533375SHEYQZ6542

Place :- Noida

Date :- 29th May 2026



For & on behalf of the board of directors

CHANDAN HEALTHCARE LIMITED

Amar Singh

Managing director

Din. :- 01096328

Place :- Lucknow

Date :- 29th May 2026

Asmita Singh

Managing director

Din. :- 01098055

Place :- Lucknow

Date :- 29th May 2026

Rajeev Nain

CFO & Company secretary

Place :- Lucknow

Date :- 29th May 2026

COMPANY NAME :- CHANDAN HEALTHCARE LIMITED

CIN :- L85110UP2003PLC193493

REGISTERED ADDRESS :- Biotech Park, Sector G, Jankipuram, Kursi Road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Audited Consolidated Statement Of Assets & Liabilities As At 31st March, 2026

Particulars	Note No.	Figures As At 31st March, 2026	Figures As At 31st March, 2025
I. EQUITY AND LIABILITIES			
(1) Shareholder's funds			
(a) Share capital	3	2,445.21	2,445.21
(b) Reserves and surplus	4	14,543.04	9,815.09
(c) Money received against share warrants	5	111.25	-
(2) Share application money pending allotment			
	0	-	-
(3) Minority interest			
	6	530.20	380.57
(4) Non-current liabilities			
(a) Long-term borrowings	7	2,897.34	2,214.46
(b) Deferred tax liabilities(net)	8	235.54	190.33
(c) Other long-term liabilities	9	2.20	2.45
(d) Long term provisions	10	460.48	343.69
(5) Current liabilities			
(a) Short-term borrowings	11	2,477.27	2,601.92
(b) Trade payables	12		
(i) Total outstanding dues of micro & small enterprises.		1,617.01	604.13
(ii) Total outstanding dues of creditors other than micro & small enterprises.		2,473.22	1,990.04
(c) Other current liabilities	13	1,052.10	438.78
(d) Short term provisions	14	106.97	69.04
TOTAL		28,951.83	21,095.71
II. ASSETS			
(1) Non-current assets			
(a) Property, plant & equipments & intangible assets	15		
(i) Property, plant & equipments		9,680.81	7,191.99
(ii) Intangible assets		443.28	443.28
(iii) Capital work in progress		1,198.83	410.12
(iv) Intangible assets under development		-	-
(b) Non-current investments	16	784.93	1,731.50
(c) Deferred tax assets(net)	17	26.27	18.04
(d) Long-term loans and advances	18	100.00	-
(e) Other non-current assets	19	246.75	253.85
(2) Current assets			
(a) Current investments	20	1,211.25	1,583.65
(b) Inventories	21	3,373.90	3,137.07
(c) Trade receivables	22	8,640.21	4,725.89
(d) Cash and bank balances	23	358.21	620.71
(e) Short-term loans and advances	24	1,763.12	410.68
(f) Other current assets	25	1,124.27	568.93
TOTAL		28,951.83	21,095.71

As per our report of even date attached

For M/s Msnt & Associates LLP

Chartered accountants

Firm registration no. :- 0185420C400322

Navodit tyagi

Partner

Membership no. :- 533375

UDIN no. :- 26533375SHEYQZ6542

Place :- Noida

Date :- 29th May 2026



For & on behalf of the board of directors

CHANDAN HEALTHCARE LIMITED



Amar singh

Managing director

Din. :- 01096328

Place :- Lucknow

Date :- 29th May 2026

Asmita singh

Managing director

Din. :- 01098055

Place :- Lucknow

Date :- 29th May 2026

Rajeev Nain

CFO & Company secretary

Place :- Lucknow

Date :- 29th May 2026

COMPANY NAME :- CHANDAN HEALTHCARE LIMITED

CIN :- L85110UP2003PLC193493

REGISTERED ADDRESS :- Biotech Park, Sector G, Jankipuram, Kursi Road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Audited Consolidated Statement Of Cash Flow For The Year Ended 31st March, 2026

Particulars	Figures For The Year Ended 31st March, 2026	Figures For The Year Ended 31st March, 2025
A. Cash flow arising from operating activities		
Profit / (Loss) before tax	3,826.66	3,206.55
Adjustments related to non-cash & non operating transactions:		
Non cash transactions		
Depreciation & amortisation of fixed assets	977.98	674.48
Bad Debts & Balances written off/written back	23.78	(124.17)
Preliminary expenses written off	-	-
Re-measurement (gains) / loss on defined benefit plans	160.50	84.27
Provision for doubtful debts	(18.53)	15.35
Provision for obsolete inventories	0.74	26.72
Loss(gain) on account of foreign exchange fluctuations	-	-
Other non-cash transactions(specify nature)	-	-
Non operating transactions		
Interest on borrowing	582.00	441.86
Loss/(profit) on the sale of property, plant & equipments & intangible assets	-	-
Loss/(profit) on the sale of investments	-	-
Interest income	(399.36)	(72.98)
Dividend income	-	-
Other non-operating transactions(specify nature)	-	-
Operating profit/(loss) before working capital changes	5,153.77	4,252.08
Adjustment for change in working capital:		
(Increase) / Decrease in inventories	(237.55)	(1,339.42)
(Increase) / Decrease in trade receivables	(3,919.57)	(1,496.39)
(Increase) / Decrease in other current assets	(556.47)	(299.92)
(Decrease) / Increase in trade payables	1,496.06	646.97
(Decrease) / Increase in other current liabilities	652.50	(1,183.74)
Net cash (used in) / generated from operating activities	2,588.74	579.57
Income taxes refund / (paid), net	(971.31)	(854.90)
Net cash flow from operating activities(A)	1,617.44	(275.33)
B. Cash flow arising from investing activities		
Sale/(Purchase) of tangible and intangible assets	(4,255.51)	(3,870.48)
Sale/(Purchase) of non current & current investments	(133.47)	(2,406.99)
Interest income	399.36	72.98
Dividend income	-	-
Net cash flow from investing activities(B)	(3,989.63)	(6,204.49)
C. Cash Flow Arising From Financing Activities		
Proceeds from issuance of share capital(Including share Warrants)	2,133.46	6,227.13
Proceeds from/(Payment of) long term & short term borrowings	558.23	1,225.27
Finance cost paid (including processing fees)	(582.00)	(441.86)
Dividend paid	-	(300.00)
Net cash flow from financing activities(C)	2,109.69	6,710.54
Net increase/decrease in cash or cash equivalents(A+B+C)	(262.50)	230.72
Cash and cash equivalents at the beginning of the period	620.71	389.99
Cash and cash equivalents at the end of the period	358.21	620.71

As per our report of even date attached
For M/s Msnt & Associates LLP
Chartered accountants

Navodit tyagi
Partner

Membership no. :- 633375

UDIN no. :- 26533375SHEYQZ6542

Place :- Noida

Date :- 29th May 2026



For & on behalf of the board of directors
CHANDAN HEALTHCARE LIMITED



Amar Singh
Managing director
Din. :- 01096328
Place :- Lucknow
Date :-

Rajeev Nain
CFO & Company secretary
Place :-
Date :- Lucknow

Asmita Singh
Managing director
Din. :- 01098055
Place :- Lucknow
Date :-

CA MSNT & ASSOCIATES LLP

CHARTERED ACCOUNTANTS

29th May, 2026.

To,
The Manager – Listing Department.
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.

Reference: - Chandan Healthcare Limited

NSE Code:-CHANDAN

ISIN: INE0B2N01016

Sub: Statement of Deviation or Variation of funds under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations) for the Quarter ended on 31st March, 2026.

Dear Sir,

Pursuant to Regulation 32 of the SEBI Listing Regulations and SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, Please find enclosed herewith a statement in this regard.

The aforesaid statement has been reviewed by the Audit Committee and taken on record by the Board at their respective meeting held on Thursday, 07 May, 2026.

This is for your information and records please.

Please take the above information on record.

Thanking You,

Yours Faithfully



📍 : **Head Office:** - A-40, I-Thum, Tower-B, 10th Floor, Unit No. 1033, Sector 62, Noida-201005.
Branch Office: - 239, Satra Plaza, Sector-19 D, Palm Beach Road, Vashi, Navi Mumbai-400703.
☎ : CA Saurabh Tyagi: 7718802884, CA Navodit Tyagi: 9167436404, CA Manoj Modi: 9022059201.
✉ : saurabh@msnt.in navodit@msnt.in manoj@msnt.in

Annexure 1-Statement of Deviation or Variation in Utilization of Funds Raised

Name of the Listed Entity	Chandan Healthcare Limited
Mode of Raising Fund	Initial Public Offer
Date of raising Fund	17th Feb, 2025
Amount Raised (Rs. in Lakhs)	7044.64
Report filed for the quarter/half year	31 ST March, 2026
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation/Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	--
If yes, Date of shareholder approval	--
Explanation for Deviation/Variation	--
Comments of the Audit Committee after review	
Comments of the Auditors, if any	

Objects for which funds have been raised and where there has been a deviation, in the following table:

Original Object	Modified Object, if any	Original Allocation (Amount in Lakhs)	Modified Allocation, if any	Funds Utilised till 31.03.2026	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
				(Amount in Lakhs)		
<i>Funding capital expenditure requirements for setting up of a flagship diagnostic centre in Ashiyana, Lucknow, Uttar Pradesh.</i>						
Funding capital expenditure towards installation of plant & machinery in our New premises along with required, electric and fabrication work	NO	710.11	0	710.11	0	
<i>Funding capital expenditure requirements for setting up of a flagship diagnostic centre in Ayodhya, Uttar Pradesh.</i>						
Funding capital expenditure towards installation of plant & machinery in our New premises along with required, electric and fabrication	NO	710.23	0	710.23	0	




work						
Funding capital expenditure requirements for setting up of a flagship diagnostic centre in Jankipuram , Lucknow, Uttar Pradesh.						
Funding capital expenditure towards installation of plant & machinery in our New premises along with required civil, electric and fabrication work	NO	3281.58	0	1627.01	0	Partially Utilised till March, 2026
General corporate purposes	NO	1672.45	0	1672.45	0	
Issue related expenses	NO	670.27	0	670.27	0	

Deviation or variation could mean:

Deviation in the Objects or purposes for which the funds have been raised or
 Deviation in the amount of funds actually utilized as against what was originally disclosed or
 Change in terms of a contract referred to in the funds raising documents I.e., prospectus, Letter of Offer

For MSNT & ASSOCIATES LLP
Chartered Accountants
Firm Registration No.018542C/C400322


 Navodit Tyagi

Partner

Membership No.-533375

UDIN No: 26533375XJDKQQ5447

Place: Noida

Date: 29/05/2026



MSNT

CHARTERED ACCOUNTANTS

MSNT & ASSOCIATES LLP CHARTERED ACCOUNTANTS

To
The Board of Directors,
Chandan Healthcare Limited
Biotech Park, Sector G, Jankipuram, Kursi Road, Jankipuram,
Lucknow, Uttar Pradesh – 226021

Statutory Auditor's Certificate certifying utilization of the Net offer proceeds received consequent to the issue of equity warrants through the Preferential issue (PI) during the quarter ended 31st March, 2026.

1. This certificate is issued in accordance with the terms of our engagement letter <dated>
2. We, MSNT & Associates LLP, Chartered Accountants (Firms' Registration No:018542C/C400322), the statutory auditors of ("the Company"), having its registered office at Biotech Park, Sector G, Jankipuram, Kursi Road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021 have examined the unaudited books of account for the period 1st January, 2026 to 31st March, 2026 to certify if the utilization of the Net offer proceeds received through the PI for the quarter ended 31st March, 2026 (included in "Annexure A") is in agreement with the unaudited books of account and in accordance with the terms of utilization included in the Notice of EGM to the PI.

Management's Responsibility for the Statement

3. Management of the Company is responsible for the appropriate utilization of funds for objects stated in the Notice to the Shareholders of the Company.
4. The Management of the Company is also responsible for the adherence to the provisions of the Companies Act, 2013 and all the applicable guidelines/ regulations specified by the Securities and Exchange Board of India ("SEBI"), the Ministry of Corporate Affairs ("MCA").

Auditor's Responsibility

5. Our responsibility is to provide limited assurance on whether the payments made representing the utilization of the Net proceeds of the PI is in agreement with the unaudited books of account and in accordance with the purposes mentioned in the Notice of EGM to PI. Nothing contained in this Certificate, nor anything said or done in the course of, or in connection with the services that are subject to this Certificate, will extend to any duty of care that we may have in our capacity of the statutory auditors of any financial statements of the Company.
6. We have conducted our examination in accordance with the Guidance Note on Reports or Certificates for Special Purposes issued by the Institute of Chartered Accountants of India ("ICAI") and Standards on Auditing specified under Section 143(10) of the Companies Act, 2013. The Guidance Note requires that we comply with the ethical requirements of the Code of Ethics issued by ICAI. The procedures performed vary in nature and timing from, and are less extent than for, a reasonable assurance. Consequently, the level of assurance obtained is substantially lower than the assurance that would have been obtained had a reasonable assurance engagement been performed.
7. We have neither performed an audit nor a review in accordance with the generally accepted auditing standards in India and accordingly we do not express any opinion on the contents of the Statement. Had we performed additional procedures in accordance with the generally accepted standards on auditing in India, other matters might have come to our attention that would have been reported.
8. Accordingly, we have performed the following procedures in relation to the Statement:



- a) Obtained and read the "Statement" for the period from 1st January, 2026 to 31st March, 2026.
 - b) Traced the "Amount as proposed in the Offer Document" from the Notice of EGM dated 14th October, 2025
 - c) Traced the Preferential Issue proceeds from the bank statement.
 - d) Verified the utilization with the supporting documents and other records including the entries in the unaudited books of account of the Company for the period from 1st January, 2026 to 31st March, 2026.
 - e) Verified the closing balances in Current Bank Account and Fixed Deposit Accounts (as mentioned in the statement) from the bank confirmation provided by the management.
 - f) Made necessary inquiries with the management and obtained relevant representations in respect of matters relating to the Statement.
9. We have complied with the relevant applicable requirements of the Standard on Quality Control (SQC) 1, Quality Control for Firms that Perform Audits and Reviews of Historical Financial Information, and Other Assurance and Related Services Engagements as issued by ICAI.

Conclusion

- g) Based on our examination, as referred above, and the information and explanations provided to us by the Management of the Company, nothing has come to our attention that causes us to believe that the utilization of the Net proceeds during the period from 1st January, 2026 to 31st March, 2026 arising from the Company's PI, read with and subject to the notes thereon (included in "Annexure A"), are not in agreement with the unaudited books of account of the Company or have not been used for the purposes as mentioned in the Notice of EGM to the PI.

Restriction on Use

10. This certificate is issued based on the request from the Management of the Company for the onward submission to monitoring agency in connection with the utilization of the proceeds from Preferential Issue under the Issue of Capital and Disclosure Requirements Regulations and should not be used by any other person or for any other purpose. Accordingly, we do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this report is shown or into whose hands it may come without our prior consent in writing.

For,
MSNT & Associates LLP
Chartered Accountants
ICAI Firm Registration No :018542C


Navodit Tyagi
Partner
Membership No :533375

Place: Noida

Date: 07/05/2026

UDIN: 26533375BLLUKA1623



“Annexure A”

Name of the issuer: Chandan Healthcare Limited

For quarter ended: 31st March, 2026

(a) Deviation from the objects: N/A

(b) Range of Deviation: N/A

Declaration:

We declare that this report provides a true and fair view of the utilization of the issue proceeds.

We declare that we do not have any direct/indirect interest in or relationship with the issuer/promoters/directors/management and also confirm that we do not perceive any conflict of interest in such relationship/interest while reporting the utilization of the issue proceeds by the issuer.

Signature:

Chandan Healthcare Limited

Authorised Signatory

Rajeev Kumar Nain
(CFO and Company Secretary)
Chandan Healthcare Limited

1) Issuer Details:

Name of the issuer: Chandan Healthcare Limited
Names of the promoter:
Industry/Sector to which it belongs: Healthcare

2) Issue Details:

Issue period: 1st January, 2026 to 31st March, 2026
Type of issue (public/rights): Preferential Issue
Type of specified securities: Share Warrants
IPO Grading, if any: N/A
Issue size (in crore/million): 104.13crores

3) Details of the arrangement made to ensure the monitoring of issue proceeds:

Particulars	Reply (Yes/No/NA)	Comments of the chartered accountant
Whether all utilization is as per the Disclosures in the Offer Document?	Yes	
Whether shareholder approval has been obtained in case of material deviations from expenditures disclosed in the Offer Document?	N/A	
Whether the means of finance for the disclosed objects of the issue has changed?	No	
Is there any major deviation observed over the earlier monitoring agency reports?	N/A	
Whether all Government/statutory approvals related to the object(s) have been obtained?	N/A	
Whether all arrangements pertaining to technical assistance/collaboration are in operation?	Yes	
Are there any favorable events improving the viability of these object(s)?	N/A	
Are there any unfavorable events affecting the viability of the object(s)?	N/A	
Is there any other relevant information that may materially affect the decision making of the investors?	No	



4) Details of object (s) s to be monitored:

(i) Cost of object (s)-

S. No.	Item Head	Original- cost as per offer document (Rs.)	Revised Cost (Rs.)	Reason of cost revision	Proposed financing option	Particulars of firm arrangements made
1	Business Expansion*	44,50,00,000	NA			
2	Acquisitions	50,00,00,000	NA			
3	GCP	9,63,00,000	NA			
	Total	1,04,13,00,000				

Note: Necessary explanation to be added, wherever applicable

* Business expansion activities also include settlement of outstanding dues payable to various vendors.

(ii) Progress in the object (s)-

S. No.	Item Head	Amount as Proposed in the offer Document (Rs.)	As at beginning of the Quarter	During the Quarter (Rs.)	At the end of the quarter (Rs.)	Total unutilized amount (Rs.)	Reasons for idle funds	Proposed course of action
1	Business Expansion	44,50,00,000	0	12,17,53,881	12,17,53,881	32,32,46,119		Amount is invested in Fixed Deposits and remaining is held as bank balance. in preferential issue account Refer Note 1 & 2
2	Acquisitions	50,00,00,000	0	0	0	50,00,00,000		Refer Note 1
3	GCP	9,63,00,000	0	4,75,54,000	4,75,54,000	4,87,46,000		Refer Note 1
	Total	1,04,13,00,000	0	16,93,07,881	16,93,07,881	87,19,92,119		

Note 1: Out of issue proceeds of Rs 1,04,13,00,000, the Company is yet to receive Rs. 78,09,75,000 (being 75% of the warrant issue size) and shall be payable by the warrant holders upon conversion of warrants into equity shares within 18 months from the date of allotment of the share warrants, i.e. by July 28, 2027, as per notice to shareholders.



Note 2: During the reported quarter ended March 31, 2026, out of the utilised proceeds of Rs. 16,93,07,881, an amount of Rs. 12,17,53,881 was transferred to current accounts of the Company for utilisation towards Object 1: Business Expansion for operational ease. The transferred proceeds were fully utilized as at end of the reported quarter.

(iii) Deployment of unutilized Preferential issue proceeds:

S. No.	Type of instrument and name of the entity invested in	Amount invested (Rs.)	Maturity date	Earning as at quarter end (31 st March, 2026)	Return on Investment (%)	Market Value as at the end of quarter (Rs.)
1	Fixed Deposits	7,31,06,811	25/02/2029	56,119	6.5% P. A	7,31,62,930
2	Bank Balance	1,79,10,308	-	-	-	1,79,10,308
	Total	9,10,17,119		56,119		9,10,73,238

Note: Necessary explanation to be added, wherever applicable

(iv) Delay in implementation of the objects:

Object(s)	Completion Date		Delay (no. of days/months)	Comments of the chartered accountant	
	As per the Offer Document	Actual		Reason of delay	Proposed course of action
		Not Applicable			

5) Details of utilization of proceeds stated as General Corporate Purpose (GCP) amount in the offer document:

S. No.	Item heads	Amount (Rs.)	Comments of the chartered accountant
1	Expenses in the ordinary course of business	4,75,54,000	Payment to Professional
	Total	4,75,54,000	





CHANDAN HEALTHCARE LIMITED

Reg. Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: L85110UP2003PLC193493

TELNO.: -8069366666 Email: secretarial@chandan.co.in

www.chandandiagnostic.com

Annexure B

Date: May 29, 2026

To,
The Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra- Kurla Complex, Bandra (East),
Mumbai - 400 051

Symbol: CHANDAN

Ref: Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sub: Declaration in respect of Audit Report with Unmodified Opinion for the Financial Year ended March 31, 2026

Dear Sir/Madam,

Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we hereby declare that M/s MSNT & Associates LLP, Chartered Accountants (Firm Registration No. 018542C), Statutory Auditors of the Company, have issued the Audit Report with unmodified opinion on the Audited Standalone and Consolidated Financial Results of the Company for the half year and financial year ended March 31, 2026.

Kindly take the above declaration on record.

Thanking you,

Yours faithfully,

For Chandan Healthcare Limited

Rajeev Kumar Nain
Chief Financial Officer

Place: Lucknow
Date: 29/05/2026



CHANDAN HEALTHCARE LIMITED

Reg. Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: L85110UP2003PLC193493

TELNO.: -8069366666 Email: secretarial@chandan.co.in

www.chandandiagnostic.com

Date: May 29, 2026

To,
The Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra- Kurla Complex, Bandra (East),
Mumbai - 400 051

Symbol: CHANDAN
ISIN: INE0B2N01016

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sub: Appointment of Internal Auditor and Cost Auditor for the financial year 2026-27

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), this is to inform that the Board of Directors of Chandan Healthcare Limited in their meeting held on May 29, 2026 (commenced at 05:00 PM (IST) & closed at ___ PM) inter-alia considered and approved the followings:

1. **Re-appointment of Internal Auditor:** Re-appointment of M/s. Renu Agrawal & Co., Chartered Accountants, as an Internal Auditor of the Company, as per the recommendation of the Audit Committee, to conduct the Internal Audit for the Financial Year 2026-27.
2. **Re-appointment of Cost Auditor:** Re-appointment of M/s. Rahul Jain & Associates, Cost Accountants, as the Cost Auditors of the Company, as per the recommendation of the Audit Committee, to conduct the Cost Audit for the Financial Year 2026-27.

The disclosures required pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, regarding the aforesaid reappointments of Internal Auditor and Cost Auditor are enclosed as Annexure I & II respectively.

The above disclosures are available on the website of the Company at www.chandandiagnostic.com

We request you to kindly take the same on record.

Thanking you,

Yours sincerely,

For Chandan Healthcare Limited

Rajeev Nain
Company Secretary & Compliance Officer

Encl.: as above



CHANDAN HEALTHCARE LIMITED

Reg. Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: L85110UP2003PLC193493

TELNO.: -8069366666 Email: secretarial@chandan.co.in

www.chandandiagnostic.com

Annexure I

Disclosures required pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 - Appointment of M/s. Renu Agrawal & Co., Chartered Accountants as the Internal Auditor of the Company

S. No.	Particulars	Details
1	Name & Details	M/s. Renu Agrawal & Co. (FRN No. 018547C) Chartered Accountants Mobile: +91-880044668 E-Mail: carajatgarg@gmail.com ; rajat@raac.in Address: Unit No. 302, Vipul Trade Centre, Sector 48, Sohna Road, Gurgaon-122018
2	Reason for Change viz., appointment/re-appointment, resignation, death or otherwise	Re-appointment
3	Date of Appointment	Reappointed for F.Y. 2026-27
4	Term of Appointment/Re-appointment	1 Year
5	Brief Profile	M/s. Renu Agrawal & Co. is a firm of Chartered Accountants in India. The Firm provides services in the fields of audit and assurance, tax and regulatory, transaction advisory and consulting keeping in mind the regulatory and commercial environment within which the Firm's clientele operate.
6	Disclosure of relationships between directors (in case of appointment of a director).	NA



CHANDAN HEALTHCARE LIMITED

Reg. Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: L85110UP2003PLC193493

TELNO.: -8069366666 Email: secretarial@chandan.co.in

www.chandandiagnostic.com

Annexure II

Disclosures required pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 - Appointment of M/s. Rahul Jain & Associates, Cost Accountants as Cost Auditor of the company

S. No.	Particulars	Details
1	Name & Details	M/s. Rahul Jain & Associates (FRN No. 101515) Cost Auditors Mobile: +91-9810720116 E-Mail: cmarahuljain@gmail.com Address: 606, Signature Global Mall Vaishali Sector-3, Ghaziabad, UP – 201010
2	Reason for Change viz., appointment/re-appointment, resignation, death or otherwise	Re-Appointment
3	Date of Appointment	Reappointed for F.Y. 2026-27
4	Term of Appointment/Re-appointment	1 Year
5	Brief Profile	M/s. Rahul Jain & Associates is a Partnership firm of Cost Accountants having a track record of providing expert services in Cost Management Accountancy. The Firm provides professional services like Cost Audit, Costing Systems, Cost Study and analysis, etc.
6	Disclosure of relationships between directors (in case of appointment of a director).	N.A.